Breaking AI & Tech News Analyzed

The Breakthrough in Addiction Treatment Results from a new clinical trial published in JAMA Network Open this month show that a single dose of psilocybin could be an effective treatment for cocaine addiction. The study found that 19 participants who received psilocybin were more likely to abstain from cocaine than 17 participants who received a placebo of diphenhydramine, a common antihistamine. Participants in both groups worked with therapists to process their experiences, highlighting the importance of the therapeutic context alongside the medication. The Urgent Need for Cocaine Addiction Treatments Dr. Peter Hendricks, a behavioral health professor at the University of Alabama at Birmingham and lead author of the study, emphasized the critical need for effective treatments. Currently, there are no FDA-approved medications for addiction to cocaine or other stimulants like methamphetamine. Overdoses involving stimulants are killing more Americans, and according to the latest UN global drug report, cocaine deaths are rising globally as cocaine production reaches an all-time high. Understanding the Mechanism Experts believe psilocybin works by increasing neuroplasticity and psychological plasticity – the ability to change thinking and behavior. Addictions inherently involve resistance to changing rigid, impulsive behaviors, which psychedelics may help overcome. Unlike traditional addiction medications that target the same neurochemical systems as the substance itself, psilocybin produces a profound altered state of consciousness within a structured psychotherapy context. It acts more like a catalyst within a therapeutic process rather than a maintenance medication. Addressing Cocaine Withdrawal Symptoms Cocaine withdrawal symptoms are primarily psychological rather than physically painful, including bad dreams, agitation, depression, and cravings. This psychological nature may make psilocybin particularly effective for cocaine addiction, as it can facilitate shifts in perspective and self-compassion that help people change their behavior. The therapeutic framework allows individuals to process their experiences and develop new insights about their addiction patterns, potentially breaking the cycle of craving and use. Diverse Clinical Trial Participation This study is notable as the first psychedelic clinical trial to include a majority of Black participants. While many spiritual rituals involving psychedelics originated in Indigenous societies in Latin America and Africa, US psychedelic culture today is often associated with Silicon Valley and elite, white personalities. Dr. Hendricks specifically recruited participants who were dependent on cocaine and wanted to stop, rather than advertising for psychedelic enthusiasts. This approach likely reduced the "expectation effect" and produced more generalizable results. Future Research Directions A critical commentary published alongside the study noted that the results might not be generally applicable because the study excluded people with comorbid depression and anxiety. However, experts point out that psilocybin shows promise for treating both conditions. The success of this trial is a clear indication that psilocybin for cocaine use disorder is a promising treatment that should proceed to larger-scale clinical trials. As research continues, the medical community may gain more insight into how psychedelics can be integrated into addiction treatment protocols.

Trump’s Public Endorsement of Psychedelic TherapiesIn a recent Guardian podcast, Donald Trump signaled support for scientific studies into psychedelic compounds, asking, “Can I have some, please?” while framing the conversation as a potential public‑health breakthrough.Funding Landscape and Recent Regulatory Milestones2023: The U.S. Food and Drug Administration granted breakthrough‑therapy designation to psilocybin for treatment‑resistant depression.2024: The National Institute on Drug Abuse allocated $150 million to clinical trials of MDMA‑assisted psychotherapy.2025: Several states, including Oregon and Colorado, legalized psilocybin for therapeutic use, creating a nascent market valued at roughly $2 billion.Potential Shift in Federal Drug PolicyTrump’s backing could influence congressional committees that oversee the Drug Enforcement Administration and the FDA. A high‑profile endorsement may:Accelerate bipartisan bills aimed at de‑scheduling certain psychedelics.Encourage the administration to prioritize research funding in upcoming budget proposals.Prompt the White House to convene a task force on psychedelic medicine.Impact on Mental‑Health Treatment ParadigmsShould policy changes follow, clinicians could gain broader access to psychedelic‑assisted therapies, potentially reducing reliance on traditional antidepressants. This aligns with growing evidence that psychedelics can produce rapid, sustained improvements for conditions such as PTSD and major depressive disorder.Looking Ahead: Political and Clinical OutlookAnalysts anticipate that Trump’s endorsement will keep psychedelics on the national agenda through the 2026 midterm elections. If legislative momentum continues, the United States could see:A federal framework for clinical trials by 2027.Expanded insurance coverage for approved psychedelic treatments by 2028.Increased private‑sector investment, potentially adding $5 billion to the market over the next five years.

The LeadResearchers at Imperial College London have shown that a single 25 mg dose of psilocybin can produce detectable anatomical changes in the brain that persist for at least a month, offering fresh clues about how psychedelics may alleviate mental‑health disorders.Single Dose of Psilocybin Triggers Measurable Brain Structure Changes28 healthy volunteers with no prior psychedelic experience participated.Participants received a low “placebo” dose (1 mg) followed, a month later, by a full psychedelic dose (25 mg).Brain activity was monitored with EEG, functional MRI, and diffusion tensor imaging (DTI).Diffusion Tensor Imaging Reveals Reduced Nerve Tract DiffusionOne month after the psychedelic dose, DTI scans showed a drop in water diffusion along front‑to‑mid‑brain nerve tracts, suggesting either pruning of existing fibres or growth of new, unmyelinated connections. The same participants also exhibited a surge in EEG‑measured brain entropy within an hour of dosing.Potential Ripple Effects on Psychedelic TherapeuticsThe anatomical shift mirrors patterns seen in ageing and dementia—where diffusion typically increases—hinting that psilocybin may promote a rejuvenating “entropic brain” state. Researchers linked the magnitude of entropy spikes to deeper psychological insight and improved wellbeing, reinforcing the hypothesis that structural plasticity underlies therapeutic outcomes. Senior author Robin Carhart-Harris described the result as “remarkable”.What This Means for Future Psychedelic Research and TreatmentLarger, longitudinal studies are needed to confirm durability of the changes.If replicated, DTI could become a biomarker for assessing psychedelic efficacy.The findings may accelerate clinical trials targeting depression, anxiety, and addiction.While promising, the study’s small sample size and indirect imaging methods warrant caution, but the evidence moves the field closer to a mechanistic understanding of psychedelic‑induced neuroplasticity.

Executive Order Accelerates Psychedelic Access in the White HouseThe White House announced a new presidential executive order on 18 April 2026 that streamlines federal approval for psychedelic‑based therapies, with a particular focus on ibogaine. The signing ceremony featured Donald Trump, Robert F. Kennedy Jr. and podcaster Joe Rogan, underscoring the political weight behind the initiative. From Senate Hearings to Presidential Sign‑off: The 60‑Year Turnaround1966 – Senator Ted Kennedy interrogates Timothy Leary about LSD, labeling it “dangerous”.2023 – Former Texas Governor Rick Perry publicly supports psychedelic legalization.2024 – Google co‑founder Sergey Brin invests $15 m in ibogaine research.2026 – Donald Trump signs the executive order, marking a dramatic policy reversal. Market Projections: Psychedelic Mushroom Industry Poised for $3.3 bn by 2031Forbes predicts the global psychedelic‑mushroom market will exceed $3.3 billion by 2031, driven by expanding legal frameworks and rising demand for novel mental‑health treatments. Earlier funding rounds illustrate the capital influx: a 2020 $125 m round backed by Peter Thiel, and a 2024 $15 m injection from Sergey Brin. Political Realignment: Why the Right Embraces Psychedelic MedicineSeveral factors explain the right‑wing pivot:Clinical evidence linking psychedelics to improvements in depression, PTSD and suicidal ideation.Veteran and law‑enforcement advocacy groups lobbying for therapeutic access.Recognition of the lucrative market, attracting Silicon Valley investors and Republican donors. What Comes Next? Regulation, Investment, and the Future of Mental‑Health CareLooking ahead, the landscape will be shaped by:Federal regulatory pathways that balance rapid approval with safety oversight.Continued venture‑capital inflows, potentially accelerating drug‑development pipelines.Political dynamics as both Democrats and MAGA Republicans champion psychedelic reform, while traditional conservatives weigh public perception.The convergence of policy, science, and finance suggests that psychedelics could become a mainstream component of mental‑health treatment within the next decade, but the ultimate trajectory will depend on how quickly regulatory frameworks adapt and who controls the emerging market.

The Executive Order That Changed Psychedelic PolicyIn a surprising move during the weekend celebrating 'Bicycle Day' – the anniversary of the first LSD trip – Donald Trump signed a landmark executive order to accelerate research into hallucinogens and increase access to them. The scene was surreal as Trump joked, 'Can I have some, please?' when discussing ibogaine, a lesser-known psychedelic known for its 12-hour trips that often provide visions of traumatic personal memories.Accelerated FDA Review ProcessThanks to the order, the US Food and Drug Administration (FDA) will fast-track the reviews of three incoming psychedelic drug candidate applications that have already received breakthrough therapy designations. These are likely to be psilocybin for two types of depression and MDMA for PTSD, a prior application for which was rejected by the FDA in 2024. This move represents the biggest greenlight the potential multibillion-dollar market has yet received, causing psychedelic company stocks to soar.Financial Implications of the Psychedelic MarketThe executive order has significant financial implications for the emerging psychedelic industry. Industry analyst Josh Hardman noted that the expected issuance of these vouchers shows just how much the White House has changed its mind on psychedelics in the last six months. The Department of Health and Human Services also announced a new $139m initiative to help spur new, effective therapies for behavioral health, including the safe use of psychedelics, with at least $50m earmarked to match state psychedelic research initiatives.Industry and Regulatory TransformationThis executive order marks a significant shift in the approach to psychedelic substances in the United States, which have been federally illegal since Richard Nixon passed the 1970 Controlled Substances Act. The order states that investigational psychedelic drugs will become available under 'right to try' legislation, which is typically reserved for terminally ill patients and those who have tried all approved treatment options. However, this sets up a potential clash with the Drug Enforcement Administration (DEA), which has previously stated that schedule I compounds are ineligible for right to try.Future Outlook for Psychedelic MedicineThe future of psychedelic medicine in the US appears to be accelerating, but with significant challenges remaining. While Trump indicated his administration is already working on rescheduling efforts, which would require approval from the DEA, concerns remain about pharmaceutical and commercial interests being the primary beneficiaries of the order. Indigenous communities that have stewarded psychedelics like ibogaine and psilocybin worry they won't be fairly compensated for their knowledge. As psychedelic reform advocate Ismail Ali noted, 'It is a substantial threshold moment,' but 'if you're looking at the US federal government for the full liberation of these plants, you're probably looking in the wrong place.' The coming years will determine whether this marks the beginning of a truly accessible psychedelic medicine future or another chapter in extraction and commercialization.

New data from the National Survey on Drug Use and Health reveal that cocaine, once a hallmark of American party culture, is losing its grip: prevalence fell to 1.5% (about 4.3 million adults) in 2024, down from 5.9 million in 2017, and use among 18‑25‑year‑olds dropped from 2.1 million to 811 000.Key DevelopmentsOverall adult cocaine use: 1.5% in 2024 vs 6.7% in early 2000s.Gen Z (18‑25) consumption fell >60% between 2017 and 2024.Purity of seized cocaine rose to 88% in 2024, up from 54% in 2020.Overdose deaths involving cocaine climbed from 10,475 in 2016 to 22,174 in 2024.Alternative substances – ketamine, psychedelics, GHB, 3‑MMC and prescription stimulants – are reported as increasingly popular in club scenes.Data & Market Impact4.3 million adults reported cocaine use in the past year (2024).Supply surge from Colombia has driven purity up, potentially intensifying health risks.Mixed‑drug environment: law‑enforcement seizures now show higher rates of cocaine combined with fentanyl or other opioids, though true contamination remains low.Why This MattersThe decline reshapes several arenas:Public health: fewer users may reduce long‑term cardiovascular disease burden, but rising overdose deaths signal a dangerous shift toward polydrug use.Law‑enforcement: reduced demand could alter trafficking routes, while higher purity may incentivize dealers to diversify into more profitable synthetics.Pharmaceutical and wellness markets: growing preference for “controlled” substances like Adderall or therapeutic ketamine points to a broader wellness‑oriented drug culture.Policy: data may prompt a re‑evaluation of the “war on drugs” narrative and encourage harm‑reduction strategies targeting mixed‑drug use.Expert InsightAnalysts attribute the shift to a convergence of cultural and economic forces. Gen Z’s heightened health consciousness and aversion to the “brash” image of cocaine drive demand toward substances perceived as safer or more therapeutic, such as ketamine, which is marketed for its antidepressant properties. At the same time, the fear of fentanyl contamination—whether statistically rare or not—creates a risk‑averse environment. Supply‑side dynamics, including record‑high Colombian output and a jump in cocaine purity to 88%, make the drug more potent, raising the stakes for accidental overdose when combined with opioids. The result is a fragmented market where cocaine is no longer the sole “star” but one component of a broader, messier drug ecosystem.What Happens NextContinued decline in pure‑cocaine use, especially among younger cohorts, is likely as alternative psych‑delics gain cultural cachet.Regulators may increase monitoring of ketamine and novel stimulants, potentially introducing new scheduling or prescription‑only frameworks.Overdose prevention efforts will need to address mixed‑drug toxicity, emphasizing testing kits and education about fentanyl‑laced supplies.Drug‑trafficking organizations could pivot toward higher‑margin synthetics, reshaping the illicit market’s geography and profit structures.

President Donald Trump signed an executive order on Saturday in the Oval Office, joined by podcaster Joe Rogan, to fast‑track the federal review of psychedelic drugs such as ibogaine, aiming to broaden treatment options for serious mental illness.The ceremony highlighted Rogan’s long‑standing advocacy for ibogaine, a plant‑derived compound used by some veteran groups to address post‑traumatic stress. Rogan recounted texting Trump about the drug, to which the president replied, “Sounds great. Do you want FDA approval? Let’s do it.”Trump framed the order as a lifeline for patients: “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.” He added that successful outcomes could have “a tremendous impact.”In a brief moment of levity, Trump joked, “Can I have some, please? I’ll take some.” He quickly refocused, noting he has no time for depression and stays busy instead.The move enjoys rare bipartisan backing, despite ibogaine and other psychedelics remaining classified under the federal government’s most restrictive drug schedule.Health Secretary Robert F. Kennedy Jr. had previously pledged to ease medical access to psychedelics, a stance echoed in the new order, which directs the Department of Health and Human Services to allocate at least $50 million to states developing programs for serious mental‑health conditions.Simultaneously, the FDA is set to issue “national priority” vouchers for three psychedelic candidates. Commissioner Marty Makary said the vouchers will enable rapid approval “if they align with our national priorities.”The agency also plans the first human trials of ibogaine in the United States, overcoming earlier concerns about potential fatal heart effects.Ibogaine’s origins trace back to the Bwiti religious ceremonies in West‑Central Africa, where the plant has been used for centuries in spiritual contexts.Former Navy SEAL Marcus Luttrell, also present at the event, praised ibogaine, stating, “It absolutely changed my life for the better.”Rogan’s endorsement and the executive order have added a new dimension to Trump’s 2024 campaign narrative, even as he has publicly questioned the administration’s stance on the war with Iran.